ArticleClinical and experimental dental research2026
Osteogenic Potential of a Three-Phase Strontium- and Silicon-Doped Tricalcium Silicate Cement on Dental Pulp Stem Cells: An In Vitro Study.
Article in Clinical and experimental dental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to evaluate the osteogenic potential of a novel three-phase cement composed of strontium-doped hydroxyapatite (Sr-HA), silicon-doped hydroxyapatite (Si-HA), and tricalcium silicate (C
methodsSr-HA, Si-HA, and C
resultsThe 3P cement exhibited excellent biocompatibility, with the highest DPSC proliferation observed at the 1/5 dilution. Apoptosis rates were minimal and comparable to controls. DPSCs cultured on 3P cement demonstrated significant increases in ALP activity, calcium deposition, and mineralized nodule formation compared to the control (p < 0.05). The osteogenic response was comparable to, or in some measures superior to, MTA and BDNT cement.
conclusionsThe three-phase Sr- and Si-doped tricalcium silicate cement supports DPSC viability and promotes osteogenic differentiation, indicating its potential as a bioactive bone substitute. Further preclinical and in vivo studies are warranted to validate its regenerative efficacy in clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.